StemCell Therapy

14 May 2012

Xenetic Biosciences plc

('Xenetic' or 'the Company')

Appointment of Vice President for Drug Development

Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, announces that Dr Henry Hoppe IV has been appointed as Vice President of Drug Development for the Company.

Dr Hoppe is a leading biotechnology drug development executive with over 20 years' experience in recombinant protein, monoclonal antibody and stem cell expression for clinical therapies. His is a key appointment for Xenetic that is a pivotal step in establishing the Company's new Drug Development Centre in Boston. Dr Hoppe's principal expertise lies in the processes surrounding regulatory submissions, IND filings and clinical trials, especially in the orphan and rare disease arena, exemplified in his 17 years at Genzyme Corporation (NasdaqGS: GENZ - news) where he was instrumental in the development and launch of many of their leading products.

About Dr Hoppe

Dr Hoppe is a biotechnology process development executive with over 20 years experience in recombinant protein, monoclonal antibody and stem cell expression for clinical therapies. He has written and reviewed IND/NDA CMC sections for numerous recombinant protein and gene therapy programs, including those for Cerezyme, Fabrazyme, Myozyme and Thyrogen, being four currently marketed products of the Genzyme Corporation. He has amassed more than 20 years experience with all aspects of therapeutic development from the bench through Phase II clinical trials including managing Clinical Manufacturing Organisations (CMOs) in both the United States and Europe (Chicago Options: ^REURUSD - news) .

Dr Hoppe graduated with a Ph.D. in Genetic Toxicology from the Massachusetts Institute of Technology (MIT) in 1980 having first gained his Bachelors degree at MIT in 1973. Between 1980 and 1984, Dr Hoppe held positions at the Harvard Medical School and the University Hospital of Boston.

From 1984 to 2001, Dr Hoppe worked for Genzyme Corporation focussing on therapies for rare genetic diseases. He was subsequently appointed Vice President of Therapeutic Development for ViaCell Inc. where he delivered stem cells to clinical trials and designed Phase II manufacturing processes.

Excerpt from:
Xenetic Biosciences - Appointment of VP for Drug Development

This entry was posted on May 14, 2012 at 11:13 am and is filed under Stem Cell kidney Failure. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |